Improving Outcomes in Patients With Refractory Idiopathic and Neurogenic Detrusor Overactivity: Management Strategies

      Abstract

      Neurogenic detrusor overactivity (NDO) is a lower urinary tract dysfunction commonly seen in rehabilitation settings. The emotional, medical, and financial consequences of NDO can be substantial and management typically requires a multidisciplinary team approach. Physiatrists need to be able to identify patients who require referral to specialists for diagnostic testing or higher-tiered treatment and need to engender open lines of communication between their patients and all treating clinicians. This requires an understanding of the evaluation, diagnosis, and treatment of neurogenic lower urinary tract dysfunctions.

      Keywords

      List of abbreviations:

      MS (multiple sclerosis), NDO (neurogenic detrusor overactivity), NLUTD (neurogenic lower urinary tract dysfunction), OAB (overactive bladder), PTNS (percutaneous tibial nerve stimulation), SCI (spinal cord injury), SNM (sacral neuromodulation), UI (urinary incontinence)
      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Archives of Physical Medicine and Rehabilitation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. International Continence Society. Terminology. Available at: http://www.ICS.org/search/defining-OAB. Accessed January 8, 2015.

        • Manack A.
        • Motsko S.P.
        • Haag-Molkenteller C.
        • et al.
        Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database.
        Neurourol Urodyn. 2011; 30: 395-401
        • Abrams P.
        • Cardozo L.
        • Fall M.
        • et al.
        The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.
        Neurourol Urodyn. 2002; 21: 167-178
        • Wein A.J.
        • Rovner E.S.
        Definition and epidemiology of overactive bladder.
        Urology. 2002; 60: 7-12
        • Samson G.
        • Cardenas D.D.
        Neurogenic bladder in spinal cord injury.
        Phys Med Rehabil Clin N Am. 2007; 18: 255-274
        • Flood H.D.
        • Ritchey M.L.
        • Bloom D.A.
        • Huang C.
        • McGuire E.J.
        Outcome of reflux in children with myelodysplasia managed by bladder pressure monitoring.
        J Urol. 1994; 152: 1574-1577
        • Jahromi M.S.
        • Mure A.
        • Gomez C.S.
        UTIs in patients with neurogenic bladder.
        Curr Urol Rep. 2014; 15: 433
        • Gormley E.A.
        Urologic complications of the neurogenic bladder.
        Urol Clin North Am. 2010; 37: 601-607
        • Pannek J.
        • Stohrer M.
        • Blok B.
        • et al.
        European Association of Urology. Guidelines on neurogenic lower urinary tract dysfunction.
        2011 (Available at:) (Accessed February 6, 2015)
        • Beeckman D.
        • Van Lancker A.
        • Van Hecke A.
        • Verhaeghe S.
        A systematic review and meta-analysis of incontinence-associated dermatitis, incontinence, and moisture as risk factors for pressure ulcer development.
        Res Nurs Health. 2014; 37: 204-218
        • Gefen A.
        From incontinence associated dermatitis to pressure ulcers.
        J Wound Care. 2014; 23: 345
        • Patel M.
        • Coshall C.
        • Rudd A.G.
        • Wolfe C.D.
        Natural history and effects on 2-year outcomes of urinary incontinence after stroke.
        Stroke. 2001; 32: 122-127
        • Brittain K.R.
        • Peet S.M.
        • Castleden C.M.
        Stroke and incontinence.
        Stroke. 1998; 29: 524-528
        • Hedman A.M.
        • Fonad E.
        • Sandmark H.
        Older people living at home: associations between falls and health complaints in men and women.
        J Clin Nurs. 2013; 22: 2945-2952
        • Lahmann N.A.
        • Heinze C.
        • Rommel A.
        [Falls in German hospitals and nursing homes 2006-2013. Frequencies, injuries, risk assessment, and preventive measures].
        Bundesgesundheitsblatt Gesundheitsofrschung Gesundheitsschutz. 2014; 57 ([German]): 650-659
        • Luppa M.
        • Luck T.
        • Weyerer S.
        • Konig H.K.
        • Riedel-Heller S.G.
        Gender differences in predictors of nursing home placement in the elderly: a systematic review.
        Int Psychogeriatr. 2009; 21: 1015-1025
        • Haab F.
        Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder.
        Neurourol Urodyn. 2014; 33: S2-S5
        • Irwin D.E.
        • Milsom I.
        • Kopp Z.
        • Abrams P.
        • Cardozo L.
        Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries.
        BJU Int. 2006; 97: 96-100
        • Tang D.H.
        • Colayco D.
        • Piercy J.
        • Patel V.
        • Globe D.
        • Chancellor M.B.
        Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity.
        BMC Neurol. 2014; 14: 74
        • Tapia C.I.
        • Khalaf K.
        • Berenson K.
        • Globe D.
        • Chancellor M.
        • Carr L.K.
        Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review.
        Health Qual Life Outcomes. 2013; 11: 13
        • Zorn B.H.
        • Montgomery H.
        • Pieper K.
        • Gray M.
        • Steers W.D.
        Urinary incontinence and depression.
        J Urol. 1999; 162: 82-84
        • Stewart W.F.
        • Van Rooyen J.B.
        • Cundiff G.W.
        • et al.
        Prevalence and burden of overactive bladder in the United States.
        World J Urol. 2003; 20: 327-336
        • Shaw C.
        A systematic review of the literature on the prevalence of sexual impairment in women with urinary incontinence and the prevalence of urinary leakage during sexual activity.
        Eur Urol. 2002; 42: 432-440
        • Fultz N.H.
        • Herzog A.R.
        Self-reported social and emotional impact of urinary incontinence.
        J Am Geriatr Soc. 2001; 49: 892-899
        • Reeves P.
        • Irwin D.
        • Kelleher C.
        • et al.
        The current and future burden and cost of overactive bladder in five European countries.
        Eur Urol. 2006; 50: 1050-1057
        • Onukwugha E.
        • Zuckerman I.H.
        • McNally D.
        • Coyne K.S.
        • Vats V.
        • Mullins C.D.
        The total economic burden of overactive bladder in the United States: a disease-specific approach.
        Am J Manag Care. 2009; 15: S90-S97
        • Coyne K.S.
        • Wein A.
        • Nicholson S.
        • Kvasz M.
        • Chen C.I.
        • Milsom I.
        Economic burden of urgency urinary incontinence in the United States: a systematic review.
        J Manag Care Pharm. 2014; 20: 130-140
        • Hu T.W.
        • Wagner T.H.
        • Bentkover J.D.
        • Leblanc K.
        • Zhou S.Z.
        • Hunt T.
        Estimated economic costs of overactive bladder in the United States.
        Urology. 2003; 61: 1123-1128
        • Hu T.W.
        • Wagner T.H.
        • Bentkover J.D.
        • Leblanc K.
        • Zhou S.Z.
        • Hunt T.
        Costs of urinary incontinence and overactive bladder in the United States: a comparative study.
        Urology. 2004; 63: 461-465
        • Mullins C.D.
        • Subak L.L.
        New perspectives on overactive bladder: quality of life impact, medication persistency, and treatment costs.
        Am J Manag Care. 2005; 11: S101-S102
      2. Chancellor MB. Part II: current treatment options for neurogenic bladder dysfunction. Renal & Neurology News. July 1, 2012. Available at: http://www.renalandurologynews.com/part-ii-current-treatment-options-for-neurogenic-bladder-dysfunction/article/248201/2/. Accessed January 8, 2015.

        • Kennelly M.J.
        • DeVoe W.B.
        Overactive bladder: pharmacologic treatments in the neurogenic population.
        Rev Urol. 2008; 10: 182-191
        • Ellsworth P.I.
        • Coyne P.K.
        • Esquenazi A.
        • et al.
        Consensus statement on neurogenic detrusor overactivity: multiple sclerosis and spinal cord injury.
        UroToday Intl J. 2012; 5: 1-18
        • Ruffion A.
        • Castro-Diaz D.
        • Patel H.
        • et al.
        Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder.
        Neuroepidemiology. 2013; 41: 146-155
        • Wein A.J.
        • Dmochowski R.R.
        Campbell-Welsh Urology.
        10th ed. Elsevier, Philadelphia2012
        • Campos-Juanatey F.
        • Gutierrez-Banos J.L.
        • Portillo-Martin J.A.
        • Zubillaga-Guerrero S.
        Assessment of the urodynamic diagnosis in patients with urinary incontinence associated with normal pressure hydrocephalus.
        Neurourol Urodyn. 2015; 34: 465-468
        • Rosenberg M.T.
        • Newman D.K.
        • Tallman C.T.
        • Page S.A.
        Overactive bladder: recognition requires vigilance for symptoms.
        Cleve Clin J Med. 2007; 74: S21-S29
        • Chancellor M.B.
        • Anderson R.J.
        • Boone T.B.
        Pharmacotherapy for neurogenic detrusor overactivity.
        Am J Phys Med Rehabil. 2006; 85: 536-545
      3. Harrington A, Bhandary A. Neurogenic detrusor overactivity after spinal cord injury. Available at: http://www.rehabmedicine.pitt.edu/docs/RGR_PDFs/RGR_8_11.pdf. Accessed December 19, 2014.

        • Mehta S.
        • Hill D.
        • McIntyre A.
        • et al.
        Meta-analysis of botulinum toxin a detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
        Arch Phys Med Rehabil. 2011; 94: 1473-1481
        • Abrams P.
        • Andersson K.E.
        • Birder L.
        • et al.
        Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence.
        Neurourol Urodyn. 2010; 29: 213-240
        • Bates D.
        • Burks J.
        • Globe D.
        • et al.
        Development of a short form and scoring algorithm from the validated actionable bladder symptom screening tool.
        BMC Neurol. 2013; 13: 78
      4. Campea S. Autonomic dysreflexia in spinal cord injury. PM&R Knowledge NOW. Available at: http://me.aapmr.org/kn/article.html?id=2. Accessed January 8, 2015.

        • Weld K.J.
        • Dmochowski R.R.
        Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury.
        Urology. 2000; 55: 490-494
      5. European Association of Urology (EAU); Lucas MG, Bedretdinova D, Bosch JLHR, et al. Guidelines on urinary incontinence (2013). Available at: http://uroweb.org/wp-content/uploads/20-Urinary-Incontinence_LR.pdf. Accessed December 19, 2014.

        • Gormley E.A.
        • Lightner D.J.
        • Burgio K.L.
        • et al.
        Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.
        J Urol. 2012; 188: 2455-2463
        • Paralyzed Veterans of America
        Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers.
        2006 (Available at:) (Accessed January 8, 2015)
        • McClurg D.
        • Ashe R.G.
        • Marshall K.
        • Lowe-Strong A.S.
        Comparison of pelvic floor muscle training, electromyography biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study.
        Neurourol Urodyn. 2006; 25: 337-346
        • Newman D.K.
        • Wein A.J.
        Office-based behavioral therapy for management of incontinence and other pelvic disorders.
        Urol Clin North Am. 2013; 40: 613-635
        • Yamaguchi O.
        • Nishizawa O.
        • Takeda M.
        • et al.
        Clinical guidelines for overactive bladder.
        Int J Urol. 2009; 16: 126-142
        • Alhasso A.A.
        • McKinlay J.
        • Patrick K.
        • Stewart L.
        Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults.
        Cochrane Database Syst Rev. 2006; : CD003193
        • Borello-France D.
        • Burgio K.L.
        Nonsurgical treatment of urinary incontinence.
        Clin Obstet Gynecol. 2004; 47: 70-82
        • Milne J.L.
        • Moore K.N.
        Factors impacting self-care for urinary incontinence.
        Urol Nurs. 2006; 26: 41-51
        • Wyndaele J.J.
        Conservative treatment of patients with neurogenic bladder.
        Eur Urol Suppl. 2008; 7: 557-565
        • Madersbacher H.
        • Mürtz G.
        • Stöhrer M.
        Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics.
        Spinal Cord. 2013; 51: 432-441
        • Bennett N.
        • O'Leary M.
        • Patel A.S.
        • Xavier M.
        • Erickson J.R.
        • Chancellor M.B.
        Can higher doses of oxybutynin improve efficacy in neurogenic bladder?.
        J Urol. 2004; 171: 749-751
        • O'Leary M.
        • Erickson J.R.
        • Smith C.P.
        • McDermott C.
        • Horton J.
        • Chancellor M.B.
        Effect of controlled release oxybutynin on neurogenic bladder function in spinal cord injury.
        J Spinal Cord Med. 2003; 26: 159-162
        • Chancellor M.
        • Boone T.
        Anticholinergics for overactive bladder therapy: central nervous system effects.
        CNS Neurosci Ther. 2012; 18: 167-174
        • Paquette A.
        • Gou P.
        • Tannenbaum C.
        Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events?.
        J Am Geriatr Soc. 2011; 59: 1332-1339
        • Wagg A.
        • Verdejo C.
        • Molander U.
        Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder.
        Int J Clin Pract. 2010; 64: 1279-1286
        • Wagg A.
        • Dale M.
        • Tretter R.
        • Stow B.
        • Compion G.
        Randomised, multicenter, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study.
        Eur Urol. 2013; 64: 74-81
        • Kay G.G.
        • Abou-Donia M.B.
        • Messer Jr., W.S.
        • Murphy D.G.
        • Tsao J.W.
        • Ouslander J.G.
        Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients.
        J Am Geriatr Soc. 2005; 53: 2195-2201
        • Natalin R.
        • Lorenzetti F.
        • Dambros M.
        Management of OAB in those over age 65.
        Curr Urol Rep. 2013; 14: 379-385
        • Chapple C.R.
        • Nitti V.W.
        • Khullar V.
        • et al.
        Onset of action of the β3-adrenoceptor agonist, mirabegron, in phase II and III clinical trials in patients with overactive bladder.
        World J Urol. 2014; 32: 1565-1572
        • Krebs J.
        • Pannek J.
        Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion.
        Spinal Cord. 2013; 51: 306-309
        • Tyagi P.
        • Thomas C.A.
        • Yoshimura N.
        • Chancellor M.B.
        Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder.
        Int Braz J Urol. 2009; 35: 76-83
        • Yamaguchi O.
        Beta3-adrenoceptors in human detrusor muscle.
        Urology. 2002; 50: 25-29
        • Andersson K.E.
        • Martin N.
        • Nitti V.
        Selective β3-adrenoceptor agonists for the treatment of overactive bladder.
        J Urol. 2013; 190: 1173-1180
        • Igawa Y.
        • Yamazaki Y.
        • Takeda H.
        • et al.
        Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders.
        J Urol. 2001; 165: 240-244
        • Nitti V.W.
        • Khullar V.
        • van Kerrebroeck P.
        • et al.
        Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomized, double-blind, placebo-controlled, phase III studies.
        Int J Clin Pract. 2013; 67: 619-632
        • Nitti V.W.
        • Auerbach S.
        • Martin N.
        • Calhoun A.
        • Lee M.
        • Herschorn S.
        Results of a randomized phase III trial of mirabegron in patients with overactive bladder.
        J Urol. 2013; 189: 1388-1395
        • Caremel R.
        • Loutochin O.
        • Corcos J.
        What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?.
        Int Urogynecol J. 2014; 25: 165-170
      6. Myrbetriq [prescribing information]. Astellas Pharma US, Northbrook2014
        • Murphy A.M.
        • Krlin R.M.
        • Goldman H.B.
        Treatment of overactive bladder: what is on the horizon?.
        Int Urogynecol J. 2013; 24: 5-13
        • Abrams P.
        • Kelleher C.
        • Staskin D.
        • et al.
        Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomized, double-blind, dose-ranging, phase 2 study (Symphony).
        Eur Urol. 2015; 67: 577-588
        • Kabay S.
        • Kabay S.C.
        • Yucel M.
        • et al.
        The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction.
        Neurourol Urodyn. 2009; 28: 964-968
        • de Sèze M.
        • Raibaut P.
        • Gallien P.
        • et al.
        Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study.
        Neurourol Urodyn. 2011; 30: 306-311
        • Leong R.K.
        • De Wachter S.G.
        • van Kerrebroeck P.E.
        Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
        Urol Int. 2010; 84: 245-253
        • Knupfer S.C.
        • Liechti M.D.
        • Mordasini L.
        • et al.
        Protocol for a randomized, placebo-controlled, double-blind clinical trial investigating sacral neuromodulation for neurogenic lower urinary tract dysfunction.
        BMC Urol. 2014; 14: 65
        • Chaabane W.
        • Guillotreau I.
        • Castel-Iacanal E.
        • et al.
        Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study.
        Neurourol Urodyn. 2011; 30: 547-550
        • Chen G.
        • Liao L.
        Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease.
        Spinal Cord. 2015; 53: 2014-2208
        • Foster Sr., R.T.
        • Anoia E.J.
        • Webster G.D.
        • Amundsen C.L.
        In patients undergoing neuromodulation for intractable urge incontinence a reduction in 24-hr pad weight after the initial test stimulation best predicts long-term patient satisfaction.
        Neurourol Urodyn. 2007; 26: 213-217
        • Scheepens W.A.
        • Van Koeveringe G.A.
        • De Bie R.A.
        • Weil E.H.
        • Van Kerrebroeck P.E.
        Long-term efficacy and safety results of the two-stage implantation technique in sacral neuromodulation.
        BJU Int. 2002; 90: 840-845
        • Siegel S.W.
        • Catanzaro F.
        • Dijkema H.E.
        • et al.
        Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention.
        Urology. 2000; 56: 87-91
        • Linsenmeyer T.A.
        Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state-of-the-art review.
        J Spinal Cord Med. 2013; 36: 402-419
        • de Sèze M.
        • Ruffion A.
        • Haab F.
        • et al.
        [Patient follow-up after botulinum toxin intradetrusor injection: proposal for management in neurogenic patients].
        Ann Readapt Med Phys. 2008; 51 ([French]): 315-321
        • Knuepfer S.
        • Juenemann K.P.
        Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice.
        Ther Adv Urol. 2014; 6: 34-42
        • Shakeri S.
        • Mohammadian R.
        • Aminsharifi A.
        • et al.
        Success rate and patients' satisfaction following intradetrusor disport injection in patients with detrusor overactivity: a comparative study of idiopathic and neurogenic types of detrusor overactivity.
        Urol J. 2014; 11: 1289-1295
        • Yonnet G.J.
        • Fieldstad A.S.
        • Carlson N.G.
        • Rose A.W.
        Advances in the management of neurogenic detrusor overactivity in multiple sclerosis.
        Int J MS Care. 2013; 15: 66-72
        • Cruz F.
        • Herschorn F.
        • Aliotta P.
        • et al.
        Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
        Eur Urol. 2011; 60: 742-750
        • Ginsberg D.
        • Gousse A.
        • Keppenne V.
        • et al.
        Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
        J Urol. 2012; 187: 2131-2139
      7. BOTOX (onabotulinumtoxinA) [prescribing information]. Allergan, Irvine2013
      8. DYSPORT (abotulinumtoxinA) [prescribing information]. Ipsen Biopharm, Wrexham2009
      9. IncobotulinumtoxinA (XEOMIN) [prescribing information]. Merz Pharmaceuticals, Greensboro2014
      10. RimabotulinumtoxinB (MYOBLOC) [prescribing information]. Solstice Neurosciences, South San Francisco2010
        • Ginsberg D.
        • Cruz F.
        • Herschorn S.
        • et al.
        OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
        Adv Ther. 2013; 30: 819-833
        • Ghalayini I.F.
        • Al-Ghazo M.A.
        • Elnasser Z.A.
        Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.
        Int Urol Nephrol. 2009; 41: 805-813
        • Becher K.
        • Oeke M.
        • Grass-Kapanke B.
        • et al.
        Improving the health care of geriatric patients: management of urinary incontinence: a position paper.
        Z Gerontol Geriatr. 2013; 46: 456-464
        • Kearns J.T.
        • Esposito D.
        • Dooley B.
        • Frim D.
        • Gundeti M.S.
        Urodynamic studies in spinal cord tethering.
        Childs Nerv Syst. 2013; 29: 1589-1600
        • Wolfe-Christensen C.
        • Manolis A.
        • Guy W.C.
        • et al.
        Bladder and bowel dysfunction: evidence for multidisciplinary care.
        J Urol. 2013; 190: 1864-1868
        • Stewart M.A.
        Effective physician-patient communication and health outcomes: a review.
        Can Med J. 1995; 152: 1423-1433
        • Schabert V.F.
        • Bavendam T.
        • Goldberg E.L.
        • Trocio J.N.
        • Brubaker L.
        Challenges for managing overactive bladder and guidance for patient support.
        Am J Manag Care. 2009; 15: A118-A122
      11. Gablofen (baclofen injection) [prescribing information]. Mallinckrodt Brand Pharmaceuticals, Hazelwood2013